12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selumetinib: Phase II data

An open-label, dose-escalation, U.S. Phase I trial in 16 patients with advanced solid tumors showed that selumetinib plus cixutumumab ( IMC-A12) produced 1 partial response and 4 cases of stable disease in 10 evaluable patients. A dose-limiting toxicity (DLT) of visual changes...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >